BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29482752)

  • 1. Non-
    Kalshetty A; Basu S
    PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET Assessment of Other Gynecologic Cancers.
    Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
    PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Assessment of Gynecologic Malignancies.
    Tripathy S; Parida GK; Kumar R
    PET Clin; 2018 Apr; 13(2):269-288. PubMed ID: 29482754
    [No Abstract]   [Full Text] [Related]  

  • 4. The Role of PET Imaging in Gynecologic Radiation Oncology.
    Rao YJ; Grigsby PW
    PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
    Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
    J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
    Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
    Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of
    Narayanan P; Sahdev A
    Br J Radiol; 2017 Nov; 90(1079):20170283. PubMed ID: 28830238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
    Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies.
    Yu JQ; Doss M; Alpaugh RK
    PET Clin; 2018 Apr; 13(2):249-268. PubMed ID: 29482753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
    Tsujikawa T; Okazawa H; Yoshida Y; Mori T; Kobayashi M; Tsuchida T; Fujibayashi Y
    Ann Nucl Med; 2008 Jan; 22(1):73-7. PubMed ID: 18250990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Imaging for Gynecologic Malignancies.
    Friedman SN; Itani M; Dehdashti F
    Radiol Clin North Am; 2021 Sep; 59(5):813-833. PubMed ID: 34392921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.
    Kitajima K; Ebina Y; Sugimura K
    Jpn J Radiol; 2014 Jun; 32(6):313-23. PubMed ID: 24744135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography in gynecological malignancies.
    Kumar R; Chauhan A; Jana S; Dadparvar S
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.